Detalhe da pesquisa
1.
FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
Br J Haematol
; 192(3): 504-513, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32621535
2.
Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.
Br J Haematol
; 173(2): 274-82, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26849853
3.
Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma.
N Engl J Med
; 378(16): 1560-1561, 2018 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29669231
4.
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Lancet
; 381(9880): 1817-26, 2013 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-23615461
5.
Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences.
Br J Haematol
; 159(2): 154-63, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22881386
6.
ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project.
Blood Adv
; 5(3): 640-648, 2021 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33560375
7.
Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling.
Blood
; 111(9): 4764-70, 2008 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18174380
8.
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
Blood
; 112(6): 2248-60, 2008 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18612102
9.
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma.
Clin Cancer Res
; 26(14): 3546-3556, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32327472
10.
Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.
Clin Cancer Res
; 13(7): 2128-35, 2007 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17404096
11.
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
J Clin Oncol
; 23(31): 7985-93, 2005 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16204016
12.
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).
J Clin Oncol
; 23(36): 9208-18, 2005 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-16314615
13.
QuantiGene Plex Represents a Promising Diagnostic Tool for Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma.
J Mol Diagn
; 17(4): 402-11, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25982535
14.
Fractionated 9°Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.
J Clin Oncol
; 32(3): 212-8, 2014 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24297953
15.
A statistical framework for analyzing hypothesized interactions between cells imaged using multispectral microscopy and multiple immunohistochemical markers.
J Pathol Inform
; 4(Suppl): S4, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23766940
16.
PLK1 and YY1 interaction in follicular lymphoma is associated with unfavourable outcome.
J Clin Pathol
; 66(9): 764-7, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23757039
17.
Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma.
JAAD Case Rep
; 4(3): 229-231, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29687056
18.
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
J Clin Oncol
; 30(14): 1647-55, 2012 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-22493413
19.
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study.
J Clin Oncol
; 30(22): 2745-52, 2012 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22734026
20.
YY1 expression predicts favourable outcome in follicular lymphoma.
J Clin Pathol
; 64(2): 125-9, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21109702